Resource Centers
Spotlight
Business
News
Conferences
Partners
CME/CE
Subscribe
- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Implementing Digital Therapeutics in Practice
Enabling DTx implementation and patient access to this category of medicine.
This framework provides healthcare decision makers (HCDM) with an industry-level guide to measuring the effectiveness of practices used to implement digital therapeutic (DTx) products in clinical settings.
The Digital Therapeutics Alliance does not provide advice on optimal business models or strategies for specific DTx products.
Payors are encouraged to use this framework for all DTx product types, with the recognition that each product has specific considerations to enable end user success.
The integration guide can be found below:
Related Content
